The rho gtpases in cancer

Channing Der and colleagues provide an encyclopedic overview of the Rho GTPases, providing enough detail to make any reader well-versed in the Rho field. The Rho GTPases in Cancer is the first volume to collect and summarize the current understanding of the Rho GTPases and their involvement in the progression of human cancer. The critical role of the Rho GTPases, their regulatory proteins, and their effectors in cancer progression has become increasingly evident over the past decade. As translational research increases on these proteins, their importance as keystone molecules in vital cellular process is highlighted. Thus, these molecules represent a major class of potential therapeutic targets that could be exploited clinically. This aspect of Rho GTPase biology is developing, therefore the contents of The Rho GTPases in Cancer should prove of interest to clinicians and members of the cancer research community wishing to develop new treatments for cancer. Channing Der and colleagues provide an encyclopedic overview of the Rho GTPases, providing enough detail to make any reader well-versed in the Rho field. Finally, Sofia Merajver’s laboratory provides an overview, which details the roles of the Rho proteins in cancer progression. She provides us with the history of the study of the Rho GTPases, their regulatory and effector proteins in cancer and gives us a benchmark of where the field is today. The second section of the book details the current knowledge of the Rho regu- tory proteins in cancer progression: aberrant expression and activation of these proteins leads to dysfunctional Rho signaling and a cancer phenotype. Gary Bokoch’s laboratory has provided a detailed overview of the role of Rho guanine dissociation inhibitors (GDIs) in cancer. These molecules are involved in preventing the Rho protein from associating with the inner plasma membrane and exchanging GDP for GTP, and thus becoming active. Next, Tozu Kazasa’s labo- tory has worked on the link between heterotrimeric G proteins and Rho activation via the RGS–RhoGEFs. This aspect of Rho activation is particularly interesting in that heterotrimeric G proteins and their associated G-protein-coupled receptors are attractive and attainable therapeutic targets. Dan Billadeau’s laboratory has worked extensively on the Vav RhoGEFs, which are potent oncogenes in their own right.

Collectif (Auteur) - Verschenen op 01/12/2009 bij Springer Libri